Download MendeleyFocused Structure-Based Virtual Screening Identifies Novel Inhibitors of SOS1.
Bonomo, S., Gibault, F., Bagal, S.K., Blackwell, J.H., Breed, J., Collie, G.W., Couturier, M., Diene, C., Di Fruscia, P., Gray, S., Hughes, C., Jeyaharan, D., Kettle, J.G., Milbradt, A.G., Northall, S., Peters, K., Stubbs, C.J., Underwood, E., Chen, Y., Hao, H., Lainchbury, M.D.(2025) ACS Med Chem Lett 16: 1905-1909
- PubMed: 41089494
- DOI: https://doi.org/10.1021/acsmedchemlett.5c00302
- Primary Citation of Related Structures:
9QFF - PubMed Abstract:
SOS1 is one of the key regulators of KRAS where it catalyzes the GTP-to-GDP turnover required for KRAS activation. Inhibition of the SOS1::KRAS interaction is an attractive strategy to modulate abnormal KRAS activation, which is responsible for several malignancies. In this work, we performed a virtual screening campaign on the AstraZeneca compound collection with Heavy Atom Count between 21 and 26 and identified two novel and efficient binders of SOS1 which fulfill the minimal pharmacophoric requirements disclosed in known compounds. Subsequently, structure- and knowledge-based approaches were applied to develop these binders into functional inhibitors of SOS1.
- Hit Discovery, Discovery Sciences, R&D, AstraZeneca, Cambridge CB2 0AA, U.K.
Organizational Affiliation:
